1	
2	
3	Healthcare provider-targeted mobile applications to diagnose, screen, or
4	monitor communicable diseases of public health importance in low- and
5	middle-income countries: a systematic review
6	
7	Pascal Geldsetzer <sup>1,2,3</sup> ¶, Sergio Flores <sup>4</sup> ¶, Blanca Flores <sup>5</sup> , Abu Bakarr Rogers <sup>6</sup> , Andrew Y Chang <sup>3,7,8*</sup>
8	
9	
10	Author Affiliations:
11	<sup>1</sup> Division of Primary Care and Population Health, Department of Medicine, Stanford University; Stanford, CA; USA
12	<sup>2</sup> Chan Zuckerberg Biohub; San Francisco, CA; USA
13	<sup>3</sup> Center for Innovation in Global Health, Stanford University; Stanford, CA; USA
14	<sup>4</sup> Department of Public Health and Caring Sciences, Uppsala University; Sweden
15	<sup>5</sup> Heidelberg University Hospital, Heidelberg; Germany
16	<sup>6</sup> Stanford University School of Medicine; Stanford, CA; USA
17	<sup>7</sup> Department of Epidemiology and Population Health, Stanford University; Stanford, CA; USA
18	<sup>8</sup> Stanford Cardiovascular Institute, Stanford University; Stanford, CA; USA
19	
20	*Corresponding Author:
21	Andrew Young Chang, MD MS
22	E-mail: aychang@stanford.edu
23	
24	<sup>¶</sup> These authors contributed equally to this work
25	Short Title: mHealth Technologies Targeting Communicable Diseases in LMICs
26	

### 27 Abstract

Communicable diseases remain a leading cause of death and disability in low-28 and middle-income countries (LMICs). mHealth technologies carry considerable 29 promise for managing these disorders within resource-poor settings, but many existing 30 applications simply represent digital versions of existing guidelines or clinical 31 calculators, communication facilitators, or patient self-management tools. 32 We thus systematically searched PubMed, Web of Science, and Cochrane 33 Central for studies published between January 2007 and October 2019 involving 34 technologies that were mobile phone- or tablet-based; able to screen for, diagnose, or 35 monitor a communicable disease of importance in LMICs; and targeted health 36 professionals as primary users. We excluded technologies that merely digitized existing 37 paper-based tools or simply facilitated communication. Extracted data included disease 38 category, pathogen type, diagnostic method, intervention purpose, study/target 39 40 population, sample size, study methodology, development stage, accessory requirement, country of development, operating system, and cost. Given the search 41 timeline and the extremely rapid turnover in the science concerning Coronavirus 42 Disease 2019 and its novel variants, studies involving it were not included in the 43 analysis. 44

Of 13,262 studies identified by the screen, 33 met inclusion criteria. 12% were
randomized clinical trials (RCTs), with 58% of publications representing technical
descriptions. 62% of studies had 100 or fewer subjects. All studied technologies
involved diagnosis or screening steps; none addressed the monitoring of infections.
52% focused on priority diseases (HIV, malaria, tuberculosis), but only 12% addressed

50	a neglected tropical disease. Although most reported studies were priced under 20USD
51	at time of publication, two thirds of the records did not yet specify a cost for the study
52	technology.
53	We conclude that there are only a small number of mHealth technologies
54	focusing on innovative methods of screening and diagnosing communicable diseases
55	potentially of use in LMICs. Rigorous RCTs, analyses with large sample size, and
56	technologies assisting in the monitoring of diseases are needed.
57	
58	
59	
60	Keywords: mHealth; mobile technology; apps; digital health; communicable diseases;
61	infectious diseases; global health; LMIC

#### **Author Summary**

64	Although significant progress has been made in decreasing their worldwide
65	impact, infectious diseases still represent a considerable burden of disease and death.
66	This is especially the case in certain regions of low- and middle-income countries,
67	where limited healthcare resources, personnel, and facilities can make it difficult to
68	provide high quality care. Mobile health (mHealth) technologies are disruptive tools that
69	hold considerable promise in these resource-constrained settings by circumventing
70	some of the aforementioned obstacles.
71	To better understand the availability and characteristics of mHealth technologies
72	for use in low- and middle-income countries, we systematically searched for studies
73	published in English between January 2007 through October 2019 to identify all existing
74	mobile phone- or tablet-based innovations targeted at healthcare providers for use
75	against infectious diseases in these settings and summarized their qualities and
76	performance.
77	We found that four times as many publications focused on tools that simply made
78	data transfer more simple than there were on new tools for detecting or monitoring
79	diseases. Few studies were tested under the most rigorous scientific methods. Many
80	diagnostic technologies we identified require specialized attachments or additional
81	laboratory equipment that connect to the smartphone or tablet, which could make their
82	use in some settings more challenging.

### 84 Introduction

As of 2019, communicable diseases were still the main driver of disability-adjusted life 85 years (DALYs) in children under ten years of age globally and were responsible for six 86 out of the top ten global causes of DALYs (1). In 2017, 35% of the years of life lost 87 worldwide were from communicable, maternal, neonatal, and nutrition-related disorders 88 (2). Communicable diseases not only increase mortality and reduce life expectancy in 89 LMICs, but they also cause significant disability, leading to loss of economic productivity 90 in impacted communities (1). Furthermore, nearly a tenth of the global burden of non-91 communicable diseases (NCDs) that year were attributed to an infectious cause, with 92 the burden guantified to be 130 million DALYs (3). Additionally, many LMICs continue to 93 be afflicted by neglected tropical diseases such as dengue virus, Chagas disease, and 94 schistosomiasis. These are not only unique to these regions but also endemic, 95 remaining a major contributor to morbidity and mortality in those settings (4–6). 96

97

The persistence of communicable diseases in LMICs is thought to be due to a number 98 of factors, including incomplete development of robust public health infrastructure, 99 shortage of healthcare providers, and continuance of major health disparities (4). New 100 technologies could help overcome these obstacles to further accelerating the reduction 101 in the communicable disease burden in LMICs. For one, such technologies could 102 enable task shifting from physicians to nurses and community health workers (CHWs) 103 with the goal of alleviating the shortage of more highly trained healthcare worker cadres 104 in low-resource settings. One venue for doing so involves equipping such personnel 105 with mobile health (mHealth) technologies, whose simplified user interfaces, integrated 106

workflow protocols, and lower costs would be ideal for extending the practice 107 capabilities of their users (7). For example, incorporating mHealth apps in routine CHW 108 activities has been shown to be beneficial in process improvement and technology 109 development, standards and guidelines, education and training, and leadership and 110 management (8). mHealth devices have already been demonstrated to improve the 111 112 management of infectious diseases in many instances in low-resource settings, (9,10) as they can serve as rapid and cheap diagnostic tools (11,12). The wireless, portable 113 aspects of many such technologies also increase the accessibility of healthcare 114 services to patients by reducing travel time and expenses (8). 115 116 The current published literature contains many reports of apps that simply digitize 117 existing algorithms or facilitate inter-provider or patient-provider communication. To the 118 best of our knowledge, however, it does not offer a comprehensive, up-to-date 119 systematic review of truly innovative, novel provider-facing mHealth technologies 120 available for infectious disease care in LMIC settings. These include technologies such 121 as simplified laboratory testing equipment with smart device interfaces and artificial 122 123 intelligence-guided diagnostic tools. As such, we conducted a systematic review that aims to identify all existing novel mobile phone- or tablet-based innovations targeted at 124 healthcare providers and summarize the performance of these technologies. 125

126


## 127 Methods

## 128 Search Strategy

129	We searched for all studies published in English from January 2007 through October
130	2019 in the following databases: Cochrane Central (searched on September 30th,
131	2019), PubMed (searched on October 7th, 2019), and Web of Science (searched on
132	October 7th, 2019). The databases were queried using keywords and medical subject
133	headings (MeSH) including those attributable to smartphones, tablets, diagnosis,
134	screening, and monitoring. A full list of the search terms used for each database are
135	shown in S1 Table. The database searches, examination of abstracts, and inspection of
136	articles' full-text versions were not conducted in duplicate. No restrictions were placed
137	on study design, sample size, or publication type. Finally, the reference lists of all
138	included studies, relevant review articles, and commentaries were screened for
139	additional references. The search process is summarized in Figure 1. The review was
140	registered in The International Prospective Register of Systematic Reviews
141	(PROSPERO; Registration number: CRD42020193945) (13). Ethical approval was not
142	sought from the Stanford institutional review board as the study did not constitute
143	human subjects research and consisted only of meta-research (which is exempt by
144	definition).
145	
146	
147	

148

149



\*Other reasons: abstracts, protocols, personal reviews, nonhuman testing. From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal. pmed1000097

8

For more information, visit www.prisma-statement.org.

### 153

## 154 Inclusion and Exclusion Criteria

155	Titles an	d abstracts were screened for pertinence, and if inconclusive, the full-text
156	versions	of articles were evaluated for adequacy utilizing the following inclusion criteria:
157	i)	The technology reported must be mobile phone or tablet-based for their
158		clinical function—this excludes mobile devices and applications that solely
159		use their internet connectivity to transmit data;
160	ii)	The technology must target healthcare professionals specifically as users—
161		tools used to educate patients, change patient behaviors as consumer
162		products, or improve patient-provider communication were excluded;
163	iii)	The technology reported must be able to screen, diagnose, or monitor a
164		disease;
165	iv)	The technology must represent an innovation—applications simply used to
166		keep records, reproduce existing guidelines and clinical calculators in digital
167		form, or facilitate communication between providers were excluded; and
168	v)	The disease the technology is designed to address must be a communicable
169		disease of public health importance for LMICs. Such diseases were defined
170		as infectious conditions that are estimated to cause more than 1% of deaths
171		in any five-year age group in the general population or among neonates, or
172		infectious diseases that have a prevalence of more than 0.1% in any five-year
173		age group in the general population or among neonates. The Global Burden
174		of Disease Project's 2019 estimates were utilized for this appraisal (14).

175

Of note, given the timeline of the search and the extremely rapid turnover in the
 science surrounding the disease and its many novel variants, studies involving
 Coronavirus Disease 2019 (COVID-19) were not included in the present analysis.

### 180 Data Extraction

The following data were extracted from each included article: author(s), title, disease or 181 risk factor, clinical domain by MeSH (15), intervention name, intervention type, purpose 182 and aim of the intervention, target population, type of diagnostic method, type of 183 pathogen studied (by microbial class, LMIC priority disease (namely Human 184 Immunodeficiency Virus (HIV), tuberculosis and malaria), as well as neglected tropical 185 disease (NTD) status as defined by the World Health Organization (16), type of mobile 186 device utilized, type of software, operating system used by intervention, study 187 population and sample size, study methods, stage of development, cost in US dollars 188 (USD) at the time of publication (all dollar figures are given as published in the 189 manuscript and not adjusted for inflation, and in the case of articles reporting currencies 190 other than dollars, were converted to 2021 US dollars (17)), country of development 191 based on first authors' institutional affiliations, location of testing based on the study 192 population country of residence, institutional nation of all listed authors, year of 193 publication, and a summary of the tool (S2 Table). These data were extracted 194 qualitatively using Microsoft Excel (Redmond, WA). 195

196

### 197 Data Analysis

Quantitative data were summarized with counts and proportions. The retrieved data 198 were organized into three themes: epidemiology, technology, and methodology. The 199 epidemiology theme described the disease of interest (and whether it is categorized as 200 an LMIC priority disease by the Global Health National Academies of Science (18) or 201 diseases that were among the top ten in terms of disability-adjusted life years caused 202 globally in 2019 (19)), its characteristics, and the geographic location of the 203 intervention's development. The technology theme described the primary hardware 204 platform of the innovation, necessary peripherals, as well as the operating system it 205 utilized and its cost considerations. The methodology theme evaluated the phase of 206 study and research design of each publication. S2 Table lists these themes, as well as 207 the categories, subcategories, and definitions that accompany them. To elucidate trends 208 among the studies, we created tables that crossed clinical categories and included all 209 the subthemes. We decided against conducting a meta-analysis due to the substantial 210 degree of heterogeneity in study designs, outcome measurements, and reporting of 211 results. As such, we employed a qualitative measure of study quality on a three-tiered (-212 213 , +, and ++) system to characterize publication quality as unsound, suboptimal, or sound, based upon the British Medical Journal's Evidence Based Medicine Best 214 Practice Toolkit (20). 215

216

### 217 **Results**

Our initial search of all the above databases retrieved 13,262 results. After duplicates were removed, abstracts screened, full texts reviewed, and articles identified from

220	reference lists of included articles were added, 33 studies met our inclusion criteria
221	(Figure 1, S3 Table). Articles were excluded if they described or evaluated: i)
222	interventions not meant for diagnosis, screening and/or monitoring (n=49); ii) non-
223	mobile technology-based interventions (n=85); iii) interventions targeting patients
224	instead of health professionals as users (n=43); iv) the general status of current
225	technologies (n=48); v) non communicable diseases (n=317), or that vi) did not have a
226	full text available (n=41); vii) were not available in English (n=14); viii) were systematic
227	reviews (n=36); ix) were study protocols or involved non-human testing (n=8); or x)
228	presented technology that merely digitalized protocols, scores or other procedures that
229	could be done on paper (n=103). An overview of the included studies' characteristics is
230	presented in <b>Table 1</b> and the full list of identified studies is available in <b>S3 Table</b> .

## Table 1. Characteristics of Studies

		Count	Percentage of Total
Year of Publication (Total N=33)	2006-2008	0	0%
	2009-2011	1	3%
	2012-2014	6	18%
	2015-2017	15	45%
	2018-2020	11	33%
Location of Study (Total N=33)	United States	13	39%
	Americas (excluding the United States)	3	9%
	Europe	3	9%
	Africa	9	27%
	Asia	5	15%
Affiliation of Researchers	United States	24	39%
(Total N=61)	Americas (excluding the United States)	7	11%
	Europe	14	23%
	Africa	9	15%
	Asia	7	11%
Aim (Total N=35)	Diagnose	26	74%
	Screen	9	26%
	Monitor	0	0%
Diagnostic Method (Total N=35)	Direct Visualization	10	29%
	Serology	11	31%
	Antigen Detection	1	3%
	Nucleic Acid Detection	10	29%
	Others	3	9%

Type of Pathogen			
Studied (Total N=42)	Viral	18	43%
	Bacterial	14	33%
	Parasitic	10	24%
Type of Device (Total N=36)	Armband/ Smartwatch	0	0%
	Smartphone	29	81%
	Non-Smartphone Mobile Phone	1	3%
	Tablet	4	11%
	iPod Device	1	3%
	Another wireless device	1	3%
Requires Use of Accessories (Total N=33)	Yes	26	79%
· · · · ·	No	7	21%
Development Stage (Total N=33)	Proof of Concept/Principle	1	3%
	In development	1	3%
	Prototype	11	33%
	Pilot	0	0%
	Validation Trial/Test in Clinical Trial	2	6%
	Available/Developed	17	52%
	Not specified	1	3%
Operating System (Total N=34)	iOS	11	32%
(100011100)	Android	18	53%
	Windows	1	3%
	Not specified	4	12%
Cost at Time of Publication (Total N=33)	0-20 USD	8	24%
	21-100 USD	2	6%
	Over 100 USD	1	3%
	Not specified/no costing yet	22	67%
Study Population Sample Size (Total N=33)	1-30	7	21%
	31-100	6	18%
	101-500	4	12%
	501-1000	1	3%
	>1000	3	9%
	None/Not specified	12	36%
Study Design (Total N=33)	Randomized Clinical Trials	4	12%
,	Observational Cohort Studies / Case-Control Studies	9	27%
	Qualitative Studies	1	3%
	Product / Technical Description	19	58%
Study Quality (Total N=33)	- (unsound)	0	0%
	+ (suboptimal)	8	24%
	++ (sound)	25	76%
Evaluation Values Used			56%
(Total N=39)	Measures of Diagnostic Accuracy	22	
(Total N=39)	Variability Measures	5	13%
(Total N=39)			13% 8%
(Total N=39)	Variability Measures	5	
(Total N=39)	Variability Measures Correlation Values Intraobserver and interobserver	5 3	8%
(Total N=39)	Variability Measures Correlation Values Intraobserver and interobserver values	5 3 1	8% 3%
(Total N=39)	Variability Measures Correlation Values Intraobserver and interobserver values Measurement Error Analysis	5 3 1 0	8% 3% 0%

235

## 236 Epidemiology

- 237 Most studies described technologies tested predominantly in the United States (13/33),
- the rest of the Americas (3/33), followed by Africa (9/33), then Asian countries (5/33)

239	and Europe (3/33). The affiliation of the first author's institutions is located
240	predominantly in the United States (24/61), with fewer based in the Americas (7/61),
241	Europe (14/61), Africa (9/61) and Asia (7/61). A noteworthy observation is that all the
242	studies save one (32/33) involved at least one researcher affiliated with a high-income
243	country institution, even if the research was ultimately conducted in an LMIC.
244	
245	Most of the identified technologies focus on the diagnosis of communicable diseases
246	(26/35), while the rest aim to screen for (9/35) these diseases. No study expressed
247	monitoring as the main aim of their technology. The diagnostic method of choice chosen
248	by the researchers was most often serological methods (11/35), followed by direct
249	visualization of the microorganisms (10/35) and nucleic acid detection (10/35). The
250	technologies targeted viral (18/42), bacterial (14/42), and parasitic (10/42) infections.
251	
252	Almost half (17/33) of the included studies addressed an LMIC priority disease. Only a
253	small number of technologies (4/33) targeted a neglected tropical disease. Table 2
254	describes the 16 studies of technologies aimed at diseases that were among the top ten
255	in terms of disability-adjusted life years (DALYs) caused globally in 2019. Specifically,
256	these studies targeted drug-susceptible tuberculosis, malaria, diarrheal diseases, and
257	lower respiratory infections.

## Table 2: Studies of technologies addressing diseases among the top ten in disability-adjusted life years globally in 2019

Title	Authors	Disease/ Risk factor	Pathogen Name	Pathogen Family/Category	Mobile Device Type	Operating System	Diagnostic Method	Clinical Domain	Researchers' Country (or countries)	Country where Research was Conducted
App-based symp toms scree ning with Xpert MTB/RIF Ultra assay used for active tuberculosis detection in migrants at point of arrivals in Italy: The E-DETECT TB intervention analysis	Barcellini, L. et al.	Pulmona ry tub erc ulos is	Mycobacterium tuberculosis	Mycobacteriaceae/ Opportunistic infection	Smartphone	Android	Nucleic Acid Detection/ Organism visualization	Infectious diseases specialists/ Pulmonology	Italy/United Kingdom	Italy
Evaluation of a Mobile Phone-Based Microscope for Screening of Schistosoma hae matobium Infection in Rural Ghana.	Bogoch, I. et al.	Schistosomia sis	Schistosoma ha ema to bium	Soil-transmitted helminthiasis	Smartphone	Windows	Organism visualization	Infectious diseases specialists/ Pediatrics/Family medicine	United States/Canada/ Ghana	Ghana
Mobile phone based clinical microscopy for global health applications.	Breslauer, D. et al.	Malaria/ Pulmonary TB	P. falciparum/ M. tuberculosis	Vector Borne Diseases/ Mycobacteriaceae- Opportunistic infection	Mobile Phone	Symbian	Organism visualization	Infectious diseases specialists	United States	United States
Evaluation of Malaria Diagnoses Using a Handheld Light Microscope in a Community-Based Setting in Rural Cote d'Ivoire.	Coulibaly, J. et al.	Malaria	Plas mo dium falcipa rum	Vector Borne Diseases	Smartphon e	iOS	Organism visualization	Infectious diseases specialists	Côte d'Ivoire/ Switzerland/ United States/ Canada	Côte d'Ivoire
Diagnosis of Schistosoma haematobium infection with a mobile phone-mounted Foldscope and a reversed-lens CellScope in Ghana.	Ephraim, R. et al.	Schistos o mia s is	Schistosoma ha ematobium	soil-transmitted helminthiasis	Smartphon e	iOS	Organism visualization	Infectious diseases specialists/ Pediatrics/Family medicine	United States/Canada/ Ghana/Switzerland	Ghana
mPneumonia: Development of an Innovative mHealth Application for Diagnosing and Treating Childhood Pneumonia and Other Childhood Illnesses in Low-Resource Settings.	Ginsburg, A. et al.	Pneumonia	Not specified	Not specified	Tablet	Androi d	Mobile health (mHealth)- based a pplications (Integrated Management of Childhood Illness algorithm)	Infectious diseases specialists/ Pediatrics/Family medicine	United States/ G hana	Ghana
A point of-need enzyme linked aptamer assay for Mycobacterium tuberculosis detection using a smartphone	L. Li, Z. Liu, H. Zhang et al	Pulmona ry tub erc ulos is	Mycobacterium tuberculosis	Mycobacteriaceae/ Opportunistic infection	Smartphon e	Android	Nucleic acid detection	Infectious diseases s pecialists/ Pulmonology	China	China
Rapid electrochemical detection on a mobile phone	Lillehoj, Peter B.; Ming-Chun Huang etal	Malaria	Plasmodium falciparum	Vector Borne Diseases	Smartphone	Android	Nucleic acid detection	Infectious diseases specialists	United States	U nited States

Integrated rapid-diagnostic-test reader platform on a cellphone	Mudanyali, Onur; Stoyan Dimitrov, Uzair Sikora, etal	Malaria/ TB/ HIV	P. falciparum, P. vivax, P. ovale and P. malariae/ M. tuberculosis/ HIV	Vector Borne Diseas ल / Mycobacteriacea e Opportunistic infection/ STD	Smartphone	Android and iOS	Serology	Infectious diseases specialists/Internal Medicine	United States	United States
Mobile phone-based evaluation of latent tuberculosis infection: proof of concept for an integrated image capture and analysis system	Naraghi, Safa; Tinashe Mutsvangw a, René Goliath et al	Latent TB	Mycobacterium sp	Mycobacteriaceae/ Opportunistic infection	Smartphone	Android	Tuberculin s kin test induration.	Infectious diseases specialists/Internal Medicine	South Africa/United Kingdom	South Africa
The Malaria System MicroApp: A New, Mobile Device-Based Tool for Malaria Diagnosis	Oliveira; Allisson Dantas, Clara Prats, Mateu Espasa, et al	Malaria	Plasmodium falciparum	Vector Borne Diseases	Ta blet	Android	Organism visualization	Infectious diseases specialists	Brazil/Spain	Brazil
Malaria Diagnosis Using a Mobile Phone Polarized Microscope	Pirnstill, C.W. & Coté, G.L.	Malaria	Plas mo dium cha ba u di	Vector Borne Diseases	Smartphone	iOS	Organism visualization	Infectious diseases specialists	United States	United States
Artificial neural network models to support the diagnosis of pleural tuberculosis in adult patients	Seixas, J.M. et al.	Pleural Tb	Mycobacterium tuberculosis	Mycobacteriaceae/ Opportunistic infection	Tablets	Not specifie d	Artificial neural net- works (ANN)	Infectious diseases specialists	Brazil/ Canada	Brazil
A paper-based microfluidic Dot-ELISA system with smartphone for the detection of influenza A	Wu, Di et al	Influenza	Influenza A virus	Ortho myxovirida e	Smartphone	Android	Serology	Infectious diseases specialists/Family medicine	United States/China	China
Deep Learning for Smartphone-based Malaria Parasite Detection in Thick Blood Smears	Yang, Feng et al	Malaria	Plas mo dium falcipa rum	Vector Borne Diseases	Smartphon e	Android	Organism visualization	Infectious diseases specialists	Unites States/China/ Thailand	Bang Iades h/ Thailand
Smartphone-Based Fluorescent Diagnostic System for Highly Pathogenic H5N1 Viruses	Yeo, Seon- Ju et al	Avian influenza	H5N1 virus	Orthomyxoviridae	Smartphon e	Android	Serology	Infectious diseases specialists/Family medicine	Republic of Korea/ Vietnam/ United States	Vietnam/ Republic of Korea

### 261 Technology

The most popular device used in the studies was the smartphone (29/36), followed by 262 tablets (4/36) and mobile phones without smartphone capabilities (1/36). Technologies 263 were predominantly developed for the Android operating system (18/34) and Apple iOS 264 (iPhone Operating System) operating system (11/34), with Windows use present in just 265 one product (1/34). Four publications did not specify an operating system used by their 266 application. Most (26/33) of the mobile technologies required the use of peripheral 267 accessories attached to them such as additional optical components, 3D printed 268 attachments, foldscopes, cradles, and dongles. Cost data were not available for most 269 (22/33) technologies. For the technologies with costing information (11/33), most were 270 priced at less than 20 USD (8/11), followed by between 20 and 100 USD (2/11) and one 271 over 100 USD (1/11) at the time of study publication. 272

273

### 274 Methodology

Most studies focused on technologies in an advanced development stage, i.e., already 275 developed and/or commercially available (17/33) followed by studies describing 276 prototypes (11/33). Regarding research design, most studies focused on descriptions of 277 the technology without a formal evaluation of its efficacy or effectiveness (19/33) or 278 assessed the technology using an observational cohort design (9/33). Only a few 279 technologies were evaluated using a randomized design (4/33). Most publications 280 reported study population sizes of less than 30 participants (7/33), followed by study 281 sizes between 31 and 100 participants (6/33), then by study sizes between 101 and 500 282

(4/33) and over 1,000 subjects (1/33). Twelve studies did not specify a study population
 size.

285

### 286 Discussion

### 287 **Principal Results**

The aim of our study was to identify and describe mobile-based technologies targeted 288 specifically at healthcare workers to screen, diagnose, and monitor communicable 289 diseases of public health importance in LMICs. We focused on technologies that 290 constituted a new tool rather than merely a digitization of an existing paper-based tool 291 or providing a means of communicating between healthcare providers. Our screening 292 found that there were four to five times as many publications on tools that merely 293 facilitated communication, transferred data, or digitized an existing paper-based 294 295 algorithm than there were on truly new tools for screening, diagnosing, and monitoring diseases. Additionally, we found that most technologies described in our study were 296 tested in high-income countries using predominantly smartphones as mobile device and 297 Android as the operating system of choice. All but one of the included studies involved 298 299 at least one author affiliated with a high-income country research institution, with 42% of first authors reporting institutional affiliations in the United States or Europe. 300

301

302 Although half of the technologies were already at an advanced stage of development,

<sup>303</sup> few were tested under the rigor of large-scale randomized controlled studies. In general,

the sample size was small, with 62% of the studies reporting 100 or fewer subjects.

Over half of the included publications were simply technical descriptions of a product. 305 Though most reported studies are of relatively affordable innovations (most under 20 306 USD), two thirds of the records did not yet specify a price point for the study technology. 307 Most importantly, all the technologies were involved in diagnosis or screening for 308 diseases—none were found to address monitoring of infections. We were, however, 309 310 encouraged to note that half of the identified technologies focused on LMIC priority communicable diseases such as HIV, malaria and tuberculosis, although only 12% 311 addressed a neglected tropical disease. 312

313

Controlling communicable disorders requires prompt screening, diagnosis, and 314 monitoring of the infectious agent, both to treat the disease in the individual and to 315 prevent its further transmission. A plethora of diagnostic tests and procedures have 316 been available to the medical community for decades, and yet, LMICs are still burdened 317 with high levels of communicable diseases (21). This has been partly explained by poor 318 availability of timely, high-quality diagnostic testing. Diagnostic laboratories in LMICs are 319 usually poorly equipped or sparsely distributed (22), limiting their ability to provide 320 321 accurate and rapid information to clinicians (23). Furthermore, the costs of building and maintaining laboratories tends to be prohibitive in resource-constrained settings (22), 322 and training specialized technical personnel requires further financial and logistic 323 324 investments that are often unavailable in these countries. Our findings seem to suggest that efforts in the development of mobile technologies have also identified laboratory-325 and imaging-based testing as key obstacles, with approximately four out of five of our 326 327 included studies focusing on diagnosis rather than screening or monitoring.

329	Furthermore, many of the diagnostic technologies we identified require the use of
330	structural appendices, optical components, or specialized laboratory equipment that
331	connect to the smartphone/tablet and its inherent software and hardware specifications.
332	Therefore, these devices are not intended to completely replace standard
333	diagnostic/screening tests and procedures, but rather to make them more accessible to
334	professionals in resource-constrained settings. That said, these innovations are also
335	limited by their disproportionate reliance on Apple iOS operating systems (as LMIC
336	mobile devices tend to run on Google Android operating systems (24,25)) and frequent
337	lack of large-scale rigorous evaluation in LMIC settings (24).
338	
339	The rather small number of innovations in this sphere reflects the likely limited public
340	health impact of the presently available device marketplace. Nevertheless, testing of
341	these technologies in LMICs, the wide range of diagnostic methods employed, and the
342	approach to a variety of emerging infectious pathogens that are being diagnosed using
343	these devices are encouraging findings. These would seem to indicate that not only are
344	these technologies being developed, but some are also entering a diversification phase,
345	which may hold promise for the field (26). Future work by mHealth researchers could
346	focus on technologies that can be scaled in a way that allows for widespread and cost-
347	effective implementation in resource-constrained health systems, while also expanding
348	their use to screen and monitor diseases rather than solely diagnose them.
349	

### 350 Limitations

Our present study has several limitations. Most importantly, we employed a restrictive 351 set of inclusion criteria, which excluded patient-facing devices and apps which digitized 352 communication, algorithms/guidelines, and clinical calculators. Such technologies may 353 have important impacts on health outcomes in resource-poor settings but were outside 354 the scope of our review. Thus, their contribution to the overall ecosystem of mHealth 355 interventions for communicable diseases in LMICs is not available here for context. 356 Next, the heterogeneity of the included studies regarding their results and 357 methodological approaches precluded us from performing a meta-analysis and 358 systematic assessment of study quality, necessitating a qualitative grading system 359 instead. Lastly, given the timeline of the search and the rapidly changing nature of the 360 field (and the infectious agent itself), studies on COVID-19 were not included. 361

362

### 363 Conclusions

This systematic review found that there are only a small number of mHealth technologies that constitute novel methods of screening, diagnosing, or monitoring communicable diseases of public health importance in LMICs. Randomized trials and evaluations with large sample sizes of these technologies are still lacking, as are applications meant to monitor diseases. Additionally, most identified products require accessories or peripheral devices, and a majority rely on operating systems not common in LMICs, thus likely precluding more widespread clinical use in these settings.

372

### 373 Acknowledgements

374 None.

375

376	Author	Contri	butions
-----	--------	--------	---------

- 377 Study concept and design: PG, SF, BF; acquisition of data: PG, SF, BF, ABR; analysis
- and interpretation of data: PG, SF, BF, ABR, AYC; drafting of the manuscript: PG, SF,
- AYC; critical revision of the manuscript: PG, SF, AYC; statistical analysis: PG, SF, AYC;
- 380 obtained funding: PG

381

### 382 Conflicts of Interest

383 No conflicts reported. Author PG is a Chan Zuckerberg Biohub investigator.

384

385

386

### 387 **References**

- 1. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden
- of 369 diseases and injuries in 204 countries and territories, 1990–2019: a
- 390 systematic analysis for the Global Burden of Disease Study 2019. The Lancet. 2020
- 391 Oct;396(10258):1204–22.
- 2. Roth Gregory A., Johnson Catherine, Abajobir Amanuel, Abd-Allah Foad, Abera
- Semaw Ferede, Abyu Gebre, et al. Global, Regional, and National Burden of

394		Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017 Jul
395		4;70(1):1–25.
396	3.	Coates MM, Kintu A, Gupta N, Wroe EB, Adler AJ, Kwan GF, et al. Burden of non-
397		communicable diseases from infectious causes in 2017: a modelling study. Lancet
398		Glob Health. 2020 Dec 1;8(12):e1489–98.
399	4.	Boutayeb A. The Burden of Communicable and Non-Communicable Diseases in
400		Developing Countries. Handb Dis Burd Qual Life Meas. 2010;531–46.
401	5.	Bangert M, Molyneux DH, Lindsay SW, Fitzpatrick C, Engels D. The cross-cutting
402		contribution of the end of neglected tropical diseases to the sustainable
403		development goals. Infect Dis Poverty. 2017 Apr 4;6(1):73.
404	6.	Bhutta ZA, Sommerfeld J, Lassi ZS, Salam RA, Das JK. Global burden, distribution,
405		and interventions for infectious diseases of poverty. Infect Dis Poverty. 2014 Jul
406		31;3:21.
407	7.	WHO   Impacts of e-health on the outcomes of care in low- and middle-income
408		countries: where do we go from here? [Internet]. WHO. World Health Organization;
409		[cited 2021 Mar 2]. Available from: https://www.who.int/bulletin/volumes/90/5/11-
410		099069/en/
411	8.	Braun R, Catalani C, Wimbush J, Israelski D. Community Health Workers and
412		Mobile Technology: A Systematic Review of the Literature. PLOS ONE. 2013 Jun

**12;8(6):e65772**.

414	9.	Yager P, Domingo GJ, Gerdes J. Point-of-Care Diagnostics for Global Health. Annu
415		Rev Biomed Eng. 2008 Jul 22;10(1):107–44.

- 10. Peeling RW, Mabey D. Point-of-care tests for diagnosing infections in the
- developing world. Clin Microbiol Infect. 2010 Aug 1;16(8):1062–9.
- 11. Park S, Zhang Y, Lin S, Wang TH, Yang S. Advances in Microfluidic PCR for Point-
- of-Care Infectious Disease Diagnostics. Biotechnol Adv. 2011 Nov;29(6):830–9.
- 12. Tokel O, Yildiz UH, Inci F, Durmus NG, Ekiz OO, Turker B, et al. Portable

421 Microfluidic Integrated Plasmonic Platform for Pathogen Detection. Sci Rep. 2015

422 Mar 24;5(1):9152.

13. Geldsetzer P, Flores B. A systematic review of mobile applications to diagnose,

screen or monitor diseases of public health importance in low-resource settings.

425 [Internet]. PROSPERO 2020 CRD42020193945. [cited 2021 Jul 4]. Available from:

https://www.crd.york.ac.uk/prospero/display\_record.php?ID=CRD42020193945

14. About GBD [Internet]. Institute for Health Metrics and Evaluation. 2014 [cited 2021

Jul 4]. Available from: http://www.healthdata.org/gbd/about

- 15. Medicine MeSH NCBI [Internet]. [cited 2021 Jul 31]. Available from:
- 430 https://www.ncbi.nlm.nih.gov/mesh/?term=medical+specialty
- 16. Control of Neglected Tropical Diseases [Internet]. [cited 2022 Jun 21]. Available
- 432 from: https://www.who.int/teams/control-of-neglected-tropical-diseases/overview

433	17. Historical currency converter with official exchange rates from 1953 [Internet]. [cited
434	2022 Jun 11]. Available from: https://fxtop.com/en/historical-currency-converter.php
435	18. Committee on Global Health and the Future of the United States, Board on Global
436	Health, Health and Medicine Division, National Academies of Sciences,
437	Engineering, and Medicine. Global Health and the Future Role of the United States
438	[Internet]. Washington, D.C.: National Academies Press; 2017 [cited 2022 Jun 21].
439	Available from: https://www.nap.edu/catalog/24737
440	19. GBD Compare   IHME Viz Hub [Internet]. [cited 2021 May 26]. Available from:
441	http://vizhub.healthdata.org/gbd-compare
442	20. Appraise the evidence   BMJ Best Practice [Internet]. [cited 2022 Jun 21]. Available
443	from: https://bestpractice.bmj.com/info/us/toolkit/learn-ebm/appraise-the-evidence/
444	21. Jayatilleke K. Challenges in Implementing Surveillance Tools of High-Income
445	Countries (HICs) in Low Middle Income Countries (LMICs). Curr Treat Options Infect
446	Dis. 2020;12(3):191–201.
447	22. Fleming KA, Horton S, Wilson ML, Atun R, DeStigter K, Flanigan J, et al. The Lancet
448	Commission on diagnostics: transforming access to diagnostics. Lancet Lond Engl.
449	2021;398(10315):1997–2050.
450	23. McNerney R. Diagnostics for Developing Countries. Diagnostics. 2015 May

451 19;5(2):200–9.

452	24. Mobile Operating System Market Share Worldwide [Internet]. StatCounter Global
453	Stats. [cited 2021 Jun 2]. Available from: https://gs.statcounter.com/os-market-
454	share/mobile/worldwide
455	25. Mobile OS market share 2019 [Internet]. Statista. [cited 2021 Mar 10]. Available
456	from: https://www.statista.com/statistics/272698/global-market-share-held-by-
457	mobile-operating-systems-since-2009/
458	26. Onodera R, Sengoku S. Innovation process of mHealth: An overview of FDA-
459	approved mobile medical applications. Int J Med Inf. 2018 Oct 1;118:65–71.